PH1004
Research-stage proposed biosimilar candidate referencing rituximab
Development code
PH1004
Reference molecule
Rituximab
Molecular target
CD20
Therapeutic area
Hematology / Autoimmune
Scientific Profile
PH1004 is a research-stage proposed biosimilar candidate referencing rituximab. The intended molecule is a recombinant chimeric murine/human IgG1 kappa monoclonal antibody directed against the CD20 antigen. Planned development activities include mammalian-cell culture process development and stepwise comparative analytical and functional studies. Biosimilarity has not been established.
Development Focus
The program is focused on comparative evaluation of molecular structure, glycan and charge profiles, purity, aggregates, stability, CD20 binding, Fcγ-receptor and C1q interactions, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and relevant B-cell lysis assays. The reference-product context includes CD20-positive B-cell malignancies and selected autoimmune or inflammatory disorders. These are not established indications for PH1004.
Proposed Mode of Action
PH1004 is designed to bind CD20 expressed on pre-B and mature B lymphocytes. Following target binding, the candidate is intended to recruit complement and immune effector cells, supporting complement-dependent and antibody-dependent mechanisms of CD20-positive B-cell lysis. These mechanisms remain subject to comparative functional confirmation.
- PH1004 is a research-stage proposed biosimilar candidate. Biosimilarity, safety, efficacy, approved indications, and interchangeability, where such a designation exists, have not been established for PH1004, and PH1004 has not been approved by any regulatory authority. References to the reference medicine, its mechanism of action, and its authorized indications are provided solely for scientific context and do not imply the same characteristics, clinical profile, or regulatory status for PH1004.
Get in touch